Vector-mediated drug delivery to the brain

Advanced Drug Delivery Reviews

Volumn 36, Issue 2-3, 1999, Pages 299-321

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Avidin; Biotin; Blood brain barrier; Drug delivery; Insulin receptor; Pharmacokinetics

Indexed keywords

BLOOD; BRAIN; DISEASES; DRUG PRODUCTS; INSULIN; NEUROPHYSIOLOGY; PHARMACOKINETICS;

ALZHEIMER'S DISEASE; AVIDIN; BIOTIN; BLOOD-BRAIN BARRIER; INSULIN RECEPTOR;

CONTROLLED DRUG DELIVERY;

ANTISENSE OLIGODEOXYNUCLEOTIDE; AVIDIN; BIOTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; INSULIN RECEPTOR; LIPOSOME; NERVE GROWTH FACTOR; NEUROTROPHIN; PEPTIDE; PEPTIDE NUCLEIC ACID; RADIOPHARMACEUTICAL AGENT; TRANSFERRIN RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

EID: 0033526159     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00087-8     Document Type: Review

References (89)

1. M.W. Brightman, T.S. Reese, N. Feder, Assessment with the electron-microscope of the permeability to peroxidase of cerebral endothelium and epithelium in mice and sharks, in: C. Crone, N.A. Lassen (Eds.), Capillary Permeability, Munksgaard, Copenhagen, 1970, p. 463.
2. Levin V.A. Relationship of octanol-water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:1980;682-684.
3. Pardridge W.M. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70:1998;1781-1792.
4. Mak M., Fung L., Strasser J.F., Saltzman W.M. Distribution of drugs following controlled delivery to the brain interstitium. J. Neuro-Oncol. 26:1995;91-102.
5. Pardridge W.M., Oldendorf W.H. Kinetics of blood-brain barrier transport of hexoses. Biochim. Biophys. Acta. 382:1975;377-392.
6. Oldendorf W.H. Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids. Am. J. Physiol. 224:1973;1450.
7. Cremer J.E., Braun L.D., Oldendorf W.H. Changes during development in transport processes of the blood-brain barrier. Biochim. Biophys. Acta. 448:1976;633-637.
8. Pardridge W.M., Connor J.D., Crawford I.L. Permeability changes in the blood-brain barrier: Causes and consequences. CRC Crit. Rev. Toxicol. 3:1975;159-199.
9. Oldendorf W.H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221:1971;1629-1639.
10. Cornford E.M., Braun L.D., Oldendorf W.H. Carrier mediated blood-brain barrier transport of choline and certain choline analogs. J. Neurochem. 30:1978;299-308.
11. Cornford E.M., Oldendorf W.H. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta. 394:1975;211-219.
12. Pardridge W.M. Receptor-mediated peptide transport through the blood-brain barrier. Endocrine Rev. 7:1986;314-330.
13. Frank H.J.L., Pardridge W.M. A direct in vitro demonstration of insulin binding to isolated brain microvessels. Diabetes. 30:1981;757-761.
14. Pardridge W.M., Eisenberg J., Yang J. Human blood-brain barrier insulin receptor. J. Neurochem. 44:1985;1771-1778.
15. Duffy K.R., Pardridge W.M. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 420:1987;32-38.
16. Broadwell R.D., Balin B.J., Salcman M. Transcytotic pathway for blood- borne protein through the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 85:1988;632-636.
17. Bickel U., Kang Y.-S., Yoshikawa T., Pardridge W.M. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate within brain capillary endothelium. J. Histochem. Cytochem. 42:1994;1493-1497.
18. Broadwell R.D., Baker-Cairns B.J., Friden P.M., Oliver C., Villegas J.C. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. Exp. Neurol. 142:1996;47-65.
19. Reinhardt R.R., Bondy C.A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 135:1994;1753-1761.
20. Golden P.L., Maccagnan T.J., Pardridge W.M. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest. 99:1997;14-18.
21. Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., Fine R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18:1987;299-304.
22. Pardridge W.M., Eisenberg J., Yang J. Human blood-brain barrier transferrin receptor. Metabolism. 36:1987;892-895.
23. Bradbury M.W.B. Transport of iron in the blood-brain-cerebrospinal fluid system. J. Neurochem. 69:1997;443-454.
24. Morris C.M., Keith A.B., Edwardson J.A., Pullen R.G.L. Uptake and distribution of iron and transferrin in the adult rat brain. J. Neurochem. 59:1992;300-306.
25. Roberts R.L., Fine R.E., Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J. Cell. Sci. 104:1993;521-532.
26. Roberts R., Sandra A., Siek G.C., Lucas J.J., Fine R.E. Studies of the mechanism of iron transport across the blood-brain barrier. Ann. Neurol. 32:1992;S43-S50.
27. Wu D., Yang J., Pardridge W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100:1997;1804-1812.
28. 125I]-transferrin through the rat blood-brain barrier in vivo. Brain Res. 683:1995;164-171.
29. Vorbrodt A.W. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol. 18:1989;359-368.
30. Huwyler J., Pardridge W.M. Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. J. Neurochem. 70:1998;883-886.
31. Descamps L., Dehouck M.-P., Torpier G., Cecchelli R. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am. J. Physiol. 270:1996;H1149-H1158.
32. Shechter Y., Maron R., Elias D., Cohen I.R. Autoantibodies to insulin receptor spontaneously develop as anti-idiotypes in mice immunized with insulin. Science. 216:1982;542-545.
33. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature. 312:1984;162-163.
34. Walus L.R., Pardridge W.M., Starzyk R.M., Friden P.M. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier following conjugation to anti- transferrin receptor antibodies. J. Pharmacol. Exp. Ther. 277:1996;1067-1075.
35. Pardridge W.M., Kang Y.-S., Buciak J.L., Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12:1995;807-816.
36. G.H. Bourne, The Rhesus Monkey, Vol. 1. Anatomy and Physiology. Academic Press, New York, 1975, pp. 6-10.
37. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P., Waldmann T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA. 86:1989;10029-10033.
38. W.M. Pardridge, Peptide Drug Delivery to the Brain. Raven Press, NY, 1991, pp. 1-357.
39. Bickel U., Yoshikawa T., Landaw E.M., Faull K.F., Pardridge W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. 90:1993;2618-2622.
40. Lodish H.F., Kong N. The secretory pathway is normal in dithiothreitol- treated cells, but disulfide-bonded proteins are reduced and reversibly retained in the endoplasmic reticulum. J. Biol. Chem. 268:1993;20598-20605.
41. Feener E.P., Shen W.-C., Ryser H.J.P. Cleavage of disulfide bonds in endocytosed macromolecules. J. Biol. Chem. 265:1990;18780-18785.
42. Wu D., Pardridge W.M. CNS pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analogue coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther. 279:1996;77-83.
43. Pardridge W.M., Boado R.J., Kang Y.-S. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. 92:1995;5592-5596.
44. Bickel U., Kang Y.-S., Pardridge W.M. In vivo cleavage of a disulfide-based chimeric opioid peptide in rat brain. Bioconj. Chem. 6:1995;211-218.
45. Pardridge W.M., Wu D., Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res. 15:1998;576-582.
46. Yoshikawa T., Pardridge W.M. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol. Exp. Ther. 263:1992;897-903.
47. Kumagai A.K., Eisenberg J., Pardridge W.M. Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J. Biol. Chem. 262:1987;15214-15219.
48. Green N.M. Avidin and streptavidin. Methods Enzymol. 184:1990;51-67.
49. Pardridge W.M., Boado R.J., Buciak J.L. Drug delivery of antisense oligonucleotides or peptides to tissues in vivo using an avidin-biotin system. Drug Del. 1:1993;43-50.
50. Bayer E.A., Wilchek M. Protein biotinylation. Methods Enzymol. 184:1990;138-160.
51. 3H]-biotin bound to different avidin analogues. J. Drug Targeting. 3:1995;159-165.
52. Morrison S.L., Shin S.-U. Genetically engineered antibodies and their application to brain delivery. Adv. Drug Deliv. Rev. 15:1995;147-175.
53. Shin S.-U., Friden P., Moran M., Olson T., Kang Y.-S., Pardridge W.M., Morrison S.L. Transferrin/antibody fusion proteins are effective in brain targeting. Proc. Natl. Acad. Sci. 92:1995;2820-2824.
54. Shin S.-U., Wu D., Ramanathan R., Pardridge W.M., Morrison S.L. Functional and pharmacokinetic properties of antibody/avidin fusion proteins. J. Immunol. 158:1997;4797-4804.
55. Capon D.J., Charnow S.M., Mordenti J., Marsters S.A., Gregory T., Mitsuya H., Byrn R.A., Lucas C., Wurm F.M., Groopman J.E., Broder S., Smith D.H. Designing CD4 immunoadhesins for AIDS therapy. Nature. 337:1989;525.
56. Weiner H.L. Oral tolerance. Proc. Natl. Acad. Sci. USA. 91:1994;10762-10765.
57. 99mTc] PnAO-biotin. Eur. J. Nucl. Med. 21:1994;314-321.
58. Suzuki Y., McMaster D., Lederis K., Rorstad O.P. Characterization of the relaxant effects of vasoactive intestinal peptide (VIP) and PHI on isolated brain arteries. Brain Res. 322:1984;9-16.
59. McCulloch J., Edvinsson L. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. Am. J. Physiol. 238:1980;H449-H456.
60. Huffman L.J., Connors J.M., Hedge G.A. VIP and its homologues increase vascular conductance in certain endocrine and exocrine glands. Am. J. Physiol. 254:1988;E435-E442.
61. O'Donnell M., Garippa R.J., O'Neill N.C., Bolin D.R., Cottrell J.M. Structure-activity studies of vasoactive intestinal polypeptide. J. Biol. Chem. 266:1991;6389-6392.
62. Maggio J.E., Stimson E.R., Ghilardi J.R., Allen C.J., Dahl C.E., Whitcomb D.C., Vigna S.R., Vinters H.V., Labenski M.E., Mantyh P.W. Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. USA. 89:1992;5462-5466.
63. 1-40/vector complex. Proc. Natl. Acad. Sci. 92:1995;10227-10231.
64. Wu D., Kang Y.-S., Bickel U., Pardridge W.M. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared to morphine. Drug Metab. Disp. 25:1997;768-771.
65. Walker L.C., Masters C., Beyreuther K., Price D.L. Amyloid in the brains of aged squirrel monkeys. Acta Neuropathol. 80:1990;381-387.
66. Martin L.J., Sangram S.S., Koo E.H., Cork L.C., Dellovade T.L., Weidemann A., Beyreuther K., Masters C., Price D.L. Amyloid precursor protein in aged nonhuman primates. Proc. Natl. Acad. Sci. USA. 88:1991;1461-1465.
67. 1-42 to a subset of senile plaques. Am. J. Pathol. 148:1996;1749-1756.
68. Hefti F. Pharmacology of neurotrophic factors. Annu. Rev. Pharmacol. Toxicol. 37:1997;239-267.
69. Pardridge W.M., Kang Y.-S., Buciak J.L. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res. 11:1994;738-746.
70. Rosenberg M.B., Hawrot E., Breakefield X.O. Receptor binding activities of biotinylated derivatives of β-nerve growth factor. J. Neurochem. 46:1986;641-648.
71. Honig B., Nicholls A. Classical electrostatics in biology and chemistry. Science. 268:1995;1144-1149.
72. Stein C.A., Cheng Y.-C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical. Science. 261:1993;1004-1011.
73. Gao W.-Y., Han F.-S., Storm C., Egan W., Cheng Y.-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41:1992;223-229.
74. Brown D.A., Kang S.-H., Gryaznov S.M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., Nereberg M.I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269:1994;26801-26805.
75. Wojcik W.J., Swoveland P., Zhang X., Vanguri P. Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of Lewis rat. J. Pharmacol. Exp. Ther. 278:1996;404-410.
76. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J.R., Neckers L.M. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc. Natl. Acad. Sci. USA. 90:1993;4665-4669.
77. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267:1993;1181-1190.
78. Tidd D.M., Vanerius H.W. Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups. Br. J. Cancer. 60:1989;343-350.
79. Boado R.J., Pardridge W.M. Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system. Bioconj. Chem. 3:1992;519-523.
80. Boado R.J., Pardridge W.M. Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates. Bioconj. Chem. 5:1994;406-410.
81. 32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin-monoclonal antibody conjugate. Drug Metab. Disp. 23:1995;55-59.
82. Boado R.J., Kang Y.-S., Wu D., Pardridge W.M. Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond. Drug Metab. Disp. 23:1995;1297-1300.
83. 3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol. Exp. Ther. 276:1996;206-211.
84. Mollegaard N.E., Buchardt O., Egholm M., Nielsen P.E. Peptide nucleic acidDNA strand displacement loops as artificial transcription promoters. Proc. Natl. Acad. Sci. USA. 91:1994;3892-3895.
85. Resnick L., Berger J.R., Shapshak P., Tourtellotte W.W. Early penetration of the blood-brain barrier by HIV. Neurology. 38:1988;9-14.
86. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA. 93:1996;14164-14169.
87. Juliano R.L., Stamp D. Pharmacokinetics of liposomes-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Bioch. Pharmacol. 27:1978;21-27.
88. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
89. Huwyler J., Yang J., Pardridge W.M. Targeted delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282:1997;1541-1546.